Artisan Partners Credits Twist Bioscience for Q2 Mid Cap Fund Gains

CHICAGO (AP) — Artisan Partners Management Co. identified synthetic biology firm Twist Bioscience Corp. as a primary driver of returns for its Artisan Mid Cap Fund during the second quarter of 2026, according to an investor letter released Monday.

The investment manager disclosed in its quarterly commentary that shares of Twist, based in South San Francisco, contributed significantly to the fund's overall performance between April and June. The disclosure comes as Artisan Partners details its portfolio holdings and strategic positioning for investors tracking the mid-cap equity strategy.

Artisan Partners, headquartered in Chicago, highlighted Twist Bioscience in the context of a broader review of the fund's activity for the period ending June 30, 2026. While the letter did not specify the exact percentage of returns attributed to the biotechnology stock, it categorized Twist as a notable contributor among the portfolio's top positions. The firm manages billions of dollars in assets and frequently cites specific holdings to illustrate its investment thesis regarding emerging technologies and life sciences sectors.

Twist Bioscience has been a focal point for investors interested in DNA synthesis and data storage applications. The company's inclusion as a performance highlight suggests that its stock price appreciated materially during the quarter, aligning with Artisan's strategy of targeting companies with disruptive potential in the mid-cap space. The investment firm noted that the holding remained a core part of the portfolio as it navigated market volatility throughout the spring and early summer months.

The release of the second-quarter letter provides transparency into the fund's composition ahead of the third quarter. Artisan Partners typically uses these communications to outline the rationale behind significant trades, whether additions or reductions in specific positions. In this instance, the emphasis on Twist Bioscience signals continued confidence in the company's operational trajectory and market position within the synthetic biology sector.

Market observers will be watching to see if Artisan maintains its weighting in Twist Bioscience as the fund moves into the final half of 2026. The biotechnology sector has faced fluctuating conditions, with investor sentiment often tied to regulatory developments and clinical trial outcomes. Whether the positive contribution noted in the second quarter will persist depends on Twist's ability to execute its growth strategy amid competitive pressures.

Investors awaiting the full third-quarter report will look for updates on whether Artisan Partners has adjusted its stance on synthetic biology stocks. The firm has not yet released guidance regarding potential changes to its top holdings for the upcoming reporting period, leaving the future allocation of capital in this sector an open question as market dynamics evolve.